ZENYF - ZENYF STOCK NEWS

Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN; OTC PINK:ZENYF) announced its SEC Form 40-F registration statement is effective, and its common stock will start trading on the Nasdaq Capital Market under the symbol ZTEK on March 22, 2022. CEO Greg Fenton stated this milestone will enhance liquidity, attract U.S. investors, and increase visibility. Zentek focuses on next-gen healthcare solutions, including ZenGUARD™, an antimicrobial coating with 99% efficacy against COVID-19, and an exclusive partnership for rapid pathogen detection technology.

Zentek Ltd. (TSX-V:ZEN, OTC:ZENYF) announced successful results from extensive testing of its icephobic coating technology. The testing, which included laboratory evaluations and real-world flight trials, showed that the coating significantly reduces ice adhesion, enhancing safety for aircraft and drones in adverse weather. The coating maintained its properties even after 1,000 hours of UV exposure, indicating durability. Future tests will explore its effectiveness against sand and rain erosion, aiming for commercialization in drone and wind turbine markets.

Zentek Ltd. (ZENYF) has engaged Vimta Labs Limited to conduct pre-clinical studies on its ZenGUARD™ active ingredient, aimed at developing a treatment for infectious skin diseases. The research will gather necessary in vitro and in vivo data for FDA drug submission. The comprehensive program includes various safety and efficacy studies, with completion expected by Q4 2022. Positive anecdotal results have been observed in human infections, and the technology demonstrates 99% antimicrobial activity, including against COVID-19. The patent application related to this technology is set to publish in June 2022.

Zentek Ltd. (ZENYF) addresses a patent claim from Graphene Composites Ltd. (GC), asserting it is frivolous and maintains that its ZenGUARD™ technology, developed in 2020, is independent and not related to GC's claims. The public examiner's response supported ZEN's position by rejecting 107 claims out of 108 from GC's patent application. ZEN is focused on commercializing its 99% antimicrobial coating and has exclusive rights to a new rapid pathogen detection technology. CEO Greg Fenton emphasizes the company's commitment to protecting its reputation and shareholder value.

Zentek Ltd. (TSXV:ZEN)(OTC PINK:ZENYF) has refuted allegations of intellectual property theft made by Graphene Composites Ltd., calling the claims frivolous. The company is currently defending itself against a lawsuit filed on January 29, 2021, assessing the risk of loss as remote. Zentek also disclosed a short position of 2,904,839 shares (under 3% of total shares outstanding) and believes the rumors are aimed to damage its credibility. Zentek is focused on next-gen healthcare solutions, including its ZenGUARD™ antimicrobial coating and rapid pathogen detection technology.

Zentek Ltd. (TSXV:ZEN, OTC PINK:ZENYF) has announced the addition of Ravi Kaza to its Advisory Board. Kaza, a finance graduate from Wharton, has over 25 years of experience in disruptive technologies, having worked in investment banking and asset management with firms like Pequot Capital and Duquesne Capital. CEO Greg Fenton expressed confidence that Kaza's expertise will significantly benefit Zentek. The company is focused on next-gen healthcare solutions, including its ZenGUARD technology, which boasts 99% antimicrobial activity against pathogens like COVID-19.

Zentek Ltd. (TSX-V:ZEN, OTC PINK:ZENYF) has secured approval to list its common stock on the Nasdaq Capital Market under the symbol ZTEK. The company will continue trading on the TSX Venture Exchange as ZEN. This strategic move aims to enhance visibility and attract U.S. investors. CEO Greg Fenton indicated that the Nasdaq listing is crucial for increasing trading liquidity and gaining greater exposure to institutional investors. Zentek is known for its innovative healthcare solutions, including its ZenGUARD antimicrobial coating.

Zentek Ltd. (TSX-V:ZEN, OTC PINK:ZENYF) provided a corporate update on February 28, 2022, announcing a strong financial position with $32 million in cash and no debt. The company purchased a research facility for $2.3 million to enhance R&D of graphene technologies. ZenGUARD™ production is approaching completion, significantly boosting manufacturing capacity. Zentek also developed universal aptamers for SARS-Cov-2 detection, awaiting regulatory approval. Icephobic coatings are undergoing trials, and several management appointments were made, marking progress in various key projects.

Zentek Ltd. (TSXV:ZEN, OTC PINK:ZENYF) announced the filing of a provisional patent for a Graphene-Wrapped Silicon Anode material, developed by researchers at the University of Waterloo. The technology aims to enhance lithium-ion batteries, demonstrating significant performance with a capacity retention of 93.3% over 100 cycles. CEO Greg Fenton noted potential for collaboration with industry partners. However, further development and optimization are required before commercialization. The research is supported by grants from NSERC and aims to replace traditional graphite anodes.